Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Expert Opinion / Interview · October 16, 2024

Olanzapine-Based Prophylactic Antiemetic Therapy for Delayed and Persistent Nausea and Vomiting in Patients With HER2-Positive or HER2-Low Breast Cancer Treated With Trastuzumab Deruxtecan

 Hitomi Sakai MD, PhD
Interview with

 

Further Reading